Oncobiologics (OTLK) Competitors $1.93 -0.03 (-1.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.95 +0.02 (+1.04%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. ACB, MNPR, IMMP, INZY, CRDF, EDIT, REPL, AVTE, BTMD, and FENCShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Aurora Cannabis (ACB), Monopar Therapeutics (MNPR), Prima BioMed (IMMP), Inozyme Pharma (INZY), Cardiff Oncology (CRDF), Editas Medicine (EDIT), Replimune Group (REPL), Aerovate Therapeutics (AVTE), biote (BTMD), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors Aurora Cannabis Monopar Therapeutics Prima BioMed Inozyme Pharma Cardiff Oncology Editas Medicine Replimune Group Aerovate Therapeutics biote Adherex Technologies Aurora Cannabis (NASDAQ:ACB) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Does the media refer more to ACB or OTLK? In the previous week, Aurora Cannabis had 2 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Aurora Cannabis and 0 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.84 beat Aurora Cannabis' score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media. Company Overall Sentiment Aurora Cannabis Neutral Oncobiologics Positive Is ACB or OTLK more profitable? Aurora Cannabis has a net margin of 1.32% compared to Oncobiologics' net margin of 0.00%. Aurora Cannabis' return on equity of 0.13% beat Oncobiologics' return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis1.32% 0.13% 0.10% Oncobiologics N/A N/A -271.12% Do insiders & institutionals have more ownership in ACB or OTLK? 47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 4.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate ACB or OTLK? Oncobiologics has a consensus price target of $9.60, suggesting a potential upside of 397.41%. Given Oncobiologics' higher possible upside, analysts plainly believe Oncobiologics is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67Oncobiologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has higher valuation & earnings, ACB or OTLK? Aurora Cannabis has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$246.72M1.02$1.63M$0.1140.73OncobiologicsN/AN/A-$75.37M-$0.91-2.12 Which has more volatility and risk, ACB or OTLK? Aurora Cannabis has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. SummaryAurora Cannabis beats Oncobiologics on 12 of the 16 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.79M$3.02B$5.53B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-2.126.3119.2822.29Price / SalesN/A309.96440.8796.30Price / CashN/A41.6335.0757.18Price / Book-0.628.488.255.54Net Income-$75.37M-$55.06M$3.25B$259.88M7 Day Performance-5.39%-3.99%-3.73%-4.66%1 Month Performance12.87%9.58%4.28%4.40%1 Year Performance-73.67%6.70%25.85%17.92% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics2.4786 of 5 stars$1.93-1.5%$9.60+397.4%-73.9%$64.79MN/A-2.1220News CoverageACBAurora Cannabis0.3625 of 5 stars$4.78-1.2%N/A-26.0%$268.86M$343.29M43.451,130Upcoming EarningsMNPRMonopar Therapeutics1.9542 of 5 stars$43.40-3.5%$60.00+38.2%+1,074.0%$265.61MN/A-12.4710Upcoming EarningsIMMPPrima BioMed1.4531 of 5 stars$1.80+4.7%$7.00+288.9%-17.1%$262.87MN/A0.002,021News CoveragePositive NewsINZYInozyme Pharma2.1102 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750News CoverageUpcoming EarningsCRDFCardiff Oncology1.7939 of 5 stars$3.73-6.0%$11.70+213.7%+14.3%$248.16M$680K-4.0520Trending NewsEarnings ReportInsider TradeOptions VolumeAnalyst RevisionGap UpHigh Trading VolumeEDITEditas Medicine3.9648 of 5 stars$2.96-6.0%$4.70+58.8%-52.5%$247.79M$35.84M-0.97230News CoverageUpcoming EarningsREPLReplimune Group3.8836 of 5 stars$3.17+0.6%$7.67+141.9%-25.6%$244.37MN/A-1.03210Trending NewsAnalyst UpgradeOptions VolumeGap DownHigh Trading VolumeAVTEAerovate TherapeuticsN/A$8.28-0.6%N/A-88.5%$240.00MN/A-2.7720High Trading VolumeBTMDbiote2.9696 of 5 stars$4.37+1.2%$8.00+83.1%-48.0%$239.08M$197.19M7.16194News CoverageUpcoming EarningsFENCAdherex Technologies1.8109 of 5 stars$8.66+0.3%$13.00+50.1%+25.0%$239.02M$30.91M-16.9810Positive News Related Companies and Tools Related Companies Aurora Cannabis Competitors Monopar Therapeutics Competitors Prima BioMed Competitors Inozyme Pharma Competitors Cardiff Oncology Competitors Editas Medicine Competitors Replimune Group Competitors Aerovate Therapeutics Competitors biote Competitors Adherex Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
